The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative

Journal of the National Cancer Institute

Volumn 108, Issue 5, 2016, Pages

  Zikos, Efstathios ^a   Coens, Corneel ^a   Quinten, Chantal ^b   Ediebah, Divine E ^a   Martinelli, Francesca ^a   Ghislain, Irina ^a   King, Madeleine T ^c   Gotay, Carolyn ^d   Ringash, Jolie ^e   Velikova, Galina ^f   Reeve, Bryce B ^g   Greimel, Eva ^h   Cleeland, Charles S ⁱ   Flechtner, Henning ^j   Taphoorn, Martin J B ^k   Weis, Joachim ^l   Schmucker Von Koch, Joseph ^m   Sprangers, Mirjam A G ⁿ   Bottomley, Andrew ^a  

^a EORTC DATA CENTER   (Belgium)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g University of North Carolina at Chapel Hill   (United States)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j OTTO VON GUERICKE UNIVERSITY   (Germany)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF FREIBURG   (Germany)

^m UNIVERSITY OF REGENSBURG   (Germany)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN CANCER; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; DETERIORATION; DISTANT METASTASIS; DYSPNEA; ESOPHAGUS CANCER; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INSOMNIA; LOSS OF APPETITE; LUNG CANCER; MELANOMA; MESOTHELIOMA; METHODOLOGY; NAUSEA; NEOPLASM; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHYSICAL ACTIVITY; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SELF REPORT; SMALL CELL LUNG CANCER; STATISTICAL ANALYSIS; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; TESTIS CANCER; UTERINE CERVIX CANCER; VOMITING; EUROPE; HEALTH STATUS; META ANALYSIS; NEOPLASMS; PATIENT SATISFACTION; PROGNOSIS; PSYCHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CONSTIPATION; EUROPE; FATIGUE; HEALTH STATUS; HUMANS; NAUSEA; NEOPLASMS; PATIENT SATISFACTION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELF REPORT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 84968861011     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv391     Document Type: Review

References (37)

1. Bottomley A, Quinten C, Coens C, et al. Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative. Eur J Cancer Care. 2009;18(2):105-107.
2. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
3. Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ- C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179-2190.
4. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18(4):775-781.
5. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26(8):1355-1363.
6. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 2011;29(15):2104-2120.
7. Zikos E, Ghislain I, Coens C, et al. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. Lancet Oncol. 2014;15(2):e78-e89.
8. Velikova G, Coens C, Efficace F, et al. Health-related quality of life in EORTC clinical trials - 30 years of progress from methodological developments to making a real impact on oncology practice. Eur J Cancer Suppl. 2012;10(1):141-149.
9. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865-871.
10. Quinten C, Martinelli F, Vercauteren J, et al. Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients. In: 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago (USA), June 2010. J Clin Oncol. 2010:28:7s (suppl; abstr 9146).
11. Quinten C, Martinelli F, Coens C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120(2):302-311.
12. Ediebah DE, Coens C, Zikos E, et al. Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer. 2014;110(10):2427-2433.
13. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851-1858.
14. Martinelli F, Quinten C, Maringwa JT, et al. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):587-599.
15. Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19(11):1753-1760.
16. Maringwa J, Quinten C, King M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol. 2011;22(9):2107-2112.
17. Ediebah DE, Coens C, Maringwa JT, et al. Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Ann Oncol. 2013;24(1):231-237.
18. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ- LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994;30A(5):635-642.
19. Hahn EA, Cella D, Chassany O, Fairclough DL, Wong GY, Hays RD. Precision of health-related quality-of-life data compared with other clinical measures. Mayo Clin Proc. 2007;82(10):1244-1254.
20. Roth BJ, Krilov L, Adams S, et al. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013;31(1):131-161.
21. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144.
22. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res. 1993;2(3):221-226.
23. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. New Jersey: Lawrence Erlbaum Associates; 1988.
24. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):171-184.
25. Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer. 2009;45(3):347-353.
26. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23(28):6854-6864.
27. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol. 2003;21(21):3909-3917.
28. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol. 2009;10(5):459-466.
29. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-2722.
30. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102-109.
31. Fairclough DL. Design and Analysis of Quality of Life Studies in the Clinical Trials. London: Chapman and Hall/CRC; 2002.
32. Bottomley A, Kirby T, Bean J, Walker J. Moving the boundaries of international collaboration on clinical trials and QoL: experiences in oncology and legislation within the European Parliament. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):43-45.
33. Quinten C, Martinelli F, Coens C, et al. Investigating heterogeneity for survival in a pooled cancer cohort of more than 10,000 patients from 30 EORTC randomized trials. In: 17th Annual Conference of the International Society for Quality of Life Research. London, UK; Poster 150/1291, Oct 2010.
34. Calvert M, Blazeby J, Revicki D, Moher D, Brundage M. Reporting quality of life in clinical trials: a CONSORT extension. Lancet. 2011;378(9804):1684-1685.
35. Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F. The CON- SORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes. 2013;11:184.
36. Ediebah DE, Galindo-Garre F, Uitdehaag BM, et al. Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res. 2015;24(4):795-804.
37. Santana MJ, Haverman L, Absolom K, et al. Training clinicians in how to use patient-reported outcome measures in routine clinical practice. Qual Life Res. 2015;24(7):1707-1718.